Vertex to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Vertex Pharmaceuticals (NASDAQ: VRTX) will participate in key investor conferences including the Jefferies London Healthcare Conference on November 16, 2022, at 9:10 a.m. GMT and the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:15 a.m. EST. Live webcasts of these events will be accessible on Vertex's website. Established in 1989, Vertex focuses on innovative treatments for serious diseases, particularly cystic fibrosis, and has a promising pipeline addressing various serious conditions. For more information, visit www.vrtx.com.

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences:

• Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 9:10 a.m. GMT (4:10 a.m. EST)
• 5^th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022, at 9:15 a.m. EST

A live webcast of management’s remarks will be available through Vertex’s website, www.vrtx.com in the “Investors” section under the “News and Events” page. A replay of the conference webcasts will be archived on the company’s website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune’s Best Workplaces in Biotechnology and Pharmaceuticals and Best Workplaces for Women. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005068/en/

Vertex Pharmaceuticals Incorporated Investor Relations:

Susie Lisa, 617-341-6108

Manisha Pai, 617-961-1899

Miroslava Minkova, 617-341-6135

Source: Vertex Pharmaceuticals Incorporated

FAQ

What events is Vertex Pharmaceuticals participating in November 2022?

Vertex Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 16, 2022, and the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022.

What time will Vertex's presentations be at the investor conferences?

The Jefferies London Healthcare Conference presentation is at 9:10 a.m. GMT, and the Evercore ISI HealthCONx Conference presentation is at 9:15 a.m. EST.

Where can I watch the Vertex Pharmaceuticals conference webcasts?

Live webcasts of the conferences can be viewed on the Vertex Pharmaceuticals website under the 'Investors' section.

What is the focus of Vertex Pharmaceuticals as a biotechnology company?

Vertex Pharmaceuticals specializes in creating transformative medicines for serious diseases, particularly cystic fibrosis, and has a robust pipeline for various conditions.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.